Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Razuprotafib in macular edema due to RVO
NCT02387788Phase 2Completed
- Sponsor
- Aerpio Therapeutics
- Start
- Jan 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of razuprotafib in macular edema and retinal vein occlusion (RVO), sponsored by Aerpio Therapeutics. Primary endpoint: Visual acuity in subjects with RVO at 84 days. Started Jan 2015; status: completed.
02
Drugs
razuprotafib
03
Conditions
macular edemaretinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT02387788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387788.